$Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa$

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa

Andexanet alfa is a recombinant factor Xa decoy protein, designed to reverse bleeding associated with oral anti-Xa agents. Andexanet alfa is also reported to neutralize the effects of heparin-related drugs. This study focused on the neutralization profiles of unfractionated heparin (UFH), enoxaparin...

Full description

Bibliographic Details
Main Authors:	Fakiha Siddiqui BDS, Alfonso Tafur MD, Emily Bontekoe BS, Omer Iqbal MD, Walter Jeske PhD, Siddharth Mehrotra, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Jawed Fareed PhD
Format:	Article
Language:	English
Published:	SAGE Publishing 2020-01-01
Series:	Clinical and Applied Thrombosis/Hemostasis
Online Access:	https://doi.org/10.1177/1076029619895120

Similar Items

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
by: Joseph Lewis BA, et al.
Published: (2022-05-01)

Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa
by: Fakiha Siddiqui BDS, et al.
Published: (2020-12-01)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
by: Siddharth Mehrotra, et al.
Published: (2022-12-01)

Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components
by: Fakiha Siddiqui BDS, et al.
Published: (2020-10-01)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
by: Fakiha Siddiqui BDS, et al.
Published: (2019-05-01)

Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version
by: Dalia Qneibi MD, et al.
Published: (2020-09-01)

Porcine Mucosal Heparin Shortage Crisis! What Are the Options?
by: Jawed Fareed PhD, et al.
Published: (2019-09-01)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
by: Jianle Chen BS, et al.
Published: (2019-04-01)

Potency Adjusted Blended Heparin of Bovine, Ovine, and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single-Sourced Porcine Heparin
by: Guy Olson BS, et al.
Published: (2023-03-01)

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
by: Alex C. Spyropoulos MD, et al.
Published: (2022-07-01)

Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium?
by: Nil Guler MD, et al.
Published: (2020-07-01)

Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates
by: Ahmed Kouta MS, MBA, et al.
Published: (2020-10-01)

Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins
by: Ahmed Kouta MS, MBA, et al.
Published: (2019-11-01)

The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients
by: Madeline Allen BS, et al.
Published: (2023-04-01)

The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients
by: Bulent Kantarcioglu MD, et al.
Published: (2022-04-01)

Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling
by: Emily Bontekoe BS, et al.
Published: (2021-05-01)

Development of an Algorithm to Predict Mortality in Patients With Sepsis and Coagulopathy
by: Amanda Walborn PhD, et al.
Published: (2020-03-01)

Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism
by: Bulent Kantarcioglu MD, et al.
Published: (2022-06-01)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial
by: André Luiz Malavasi Longo de Oliveira MD, MSc, et al.
Published: (2022-12-01)

Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism
by: Alexander O’Hara BS, et al.
Published: (2023-03-01)

The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients
by: Mark Jaradeh BS, et al.
Published: (2021-10-01)

Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation
by: Amanda Walborn PhD, et al.
Published: (2019-05-01)

Biomarkers of Platelet Activation and Their Prognostic Value in Patients With Sepsis-Associated Disseminated Intravascular Coagulopathy
by: Gracelene Wegrzyn MD, et al.
Published: (2021-02-01)

Successful use of an antithrombin for heparin resistance with andexanet alfa
by: Jun Honda, et al.
Published: (2023-05-01)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
by: C. James Watson, et al.
Published: (2019-11-01)

Endogenous Glycosaminoglycans in Various Pathologic Plasma Samples as Measured by a Fluorescent Quenching Method
by: Bulent Kantarcioglu MD, et al.
Published: (2022-12-01)

Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review
by: Nicholas Kipshidze MD, PhD, DSc, et al.
Published: (2020-09-01)

Update on the safety and bioequivalence of biosimilars – focus on enoxaparin
by: Jeske W, et al.
Published: (2013-06-01)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
by: Thompson David, et al.
Published: (2006-09-01)

Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey
by: Charles Fasanya MD, FRCS FACS, et al.
Published: (2024-03-01)

Markers of Inflammation and Infection in Sepsis and Disseminated Intravascular Coagulation
by: Priya Patel BS, et al.
Published: (2019-04-01)

The refractory effective of unfractionated heparin during an open aneurysm repair post-andexanet administration: A case report
by: Laura T. Boitano, et al.
Published: (2022-06-01)

Regulation of Cortisol in Patients Undergoing Total Joint Arthoplasty
by: Rajan Khanna MD, et al.
Published: (2021-04-01)

Venous Thromboembolism Prophylaxis with Enoxaparin Versus Unfractionated Heparin in Patients with Low Body Weight
by: David Michael Kaylor PharmD, et al.
Published: (2023-02-01)

Interrelationship Between Inflammatory Biomarkers and Collagen Remodeling Proteins in Atrial Fibrillation
by: Ameer Odeh BS, et al.
Published: (2023-03-01)

Collagen Remodeling and Fatty Acid Regulation Biomarkers in Understanding the Molecular Pathogenesis of Atrial Fibrillation
by: Ameer Odeh BS, et al.
Published: (2022-12-01)

Arterial-renal Syndrome in Patients with ESRD, a New Disease Paradigm
by: Jake Goldstein, et al.
Published: (2022-01-01)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
by: Alpesh Amin, et al.
Published: (2023-06-01)

PERBANDINGAN KUALITAS HIDUP PENDERITA SINDROMA KORONER AKUT DENGAN TERAPI HEPARIN DAN FONDAPARINUX
by: , KUSUMAWARDHANI ANDANASARI, et al.
Published: (2013)

Pulmonary and intracranial miliary tuberculosis secondary to Behçet's anti-TNF alfa treatment
by: Asmae Sekkat, MD, et al.
Published: (2021-02-01)